We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Siemens and Sysmex Sign Global Hemostasis Supply Agreement

By LabMedica International staff writers
Posted on 10 Mar 2023
Print article
Image: Sysmex and Siemens have established global agreement to supply hemostasis instruments and reagents as OEMs (Photo courtesy of Sysmex)
Image: Sysmex and Siemens have established global agreement to supply hemostasis instruments and reagents as OEMs (Photo courtesy of Sysmex)

Sysmex Corporation (Kobe, Japan) and Siemens Healthcare Diagnostics Inc. (Siemens Healthineers, Erlangen, Germany) have signed a global OEM agreement on hemostasis products under which each company will supply the other with their products in the diagnostic field of hemostasis on an OEM basis.

Both Siemens and Sysmex provide hemostasis products used in testing for blood clotting disorders, preoperative bleeding risk management, and the monitoring of patients receiving anticoagulant therapy medications. Following their global agreement on distribution, sales, and services for hemostasis products signed in 1995, the two companies have since then developed a strong partnership and gone on to become one of the leading solution providers in the global hemostasis space. Over this period, the companies have further expanded their capabilities and gained strength by introducing new innovations in their product portfolios.

The demand for hemostasis has recently increased and become more diverse due to rising incidence of thrombotic diseases as a result of lifestyle diseases, development of new blood preparations, use in testing to predict COVID-19 severity, as well as higher demand for standardization, IT connectivity, and quality improvement in testing. Under the OEM agreement Sysmex and Siemens will individually offer laboratories even more compelling, effective hemostasis solutions globally, with the objective of addressing the changing testing environments of their customers and improving access to care in order to improve outcomes for patients across the world. Both the companies have further demonstrated their commitment to continue advancing hemostasis testing through their strengthened partnership.

The OEM agreement will allow both companies to distribute - globally and individually - under their respective brands their combined portfolio of hemostasis instruments and reagents, alongside their own wider portfolios of products and services. Going forward, the companies will each individually offer effective solutions to laboratories across the world that build on their respective strengths, based on one of the world’s most extensive hemostasis product portfolios achieved through the collaboration in order to meet diversifying client needs.

“Making our long-standing partnership with Siemens Healthineers even more sustainable, we remain committed to further enhance the value of hemostasis testing as a global leader,” said Kenji Tachibana, Member of the Managing Board and Senior Executive Officer, Senior Managing Director of Sysmex. “We will individually offer laboratories worldwide proprietary solutions with the benefit of our respective expertise and service portfolio, providing customers with access to the broadest set of solutions in the evolving market.”

"Siemens Healthineers and Sysmex have built a solid hemostasis partnership for more than 25 years," said Sharon Bracken, Head of Diagnostics for Siemens Healthineers. "The time has come to offer one of the world’s most extensive product portfolios achieved through mutual OEM supply to benefit customers and patients worldwide. With the OEM agreement, we will more effectively deliver quality and comprehensive hemostasis testing solutions to laboratories of all sizes across the world."

Related Links:
Siemens Healthineers
Sysmex Corporation 

New
Gold Member
Chagas Disease Test
CHAGAS Cassette
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Blood Culture Identification Panel
cobas ePlex BCID-GP Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.